ArticlePLoS medicine2026
Potential health impacts and costs of active case finding guided by Mycobacterium tuberculosis immunoreactivity survey results in Blantyre, Malawi: A mathematical modeling study.
Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundActive case finding (ACF) for tuberculosis (TB) can reduce transmission, yet efficient targeting requires high-quality surveillance data. We investigated the potential costs and impact of targeted ACF, guided by local estimates of the annual risk of TB infection (ARTI) derived from Mycobacterium tuberculosis (Mtb) immunoreactivity survey data in children aged <5 years. METHODS AND
findingsUsing mathematical models parameterized with local data, we compared three case-finding approaches across 33 urban neighborhoods in Blantyre, Malawi: passive case finding (PCF) only; PCF with untargeted ACF; and PCF with ARTI-guided targeted ACF. Health outcomes (life expectancy, disability-adjusted life years [DALYs]) and costs were estimated using a Markov microsimulation model. Costs were assessed from health system and societal perspectives. Results were calculated for different assumptions about the relationship between ARTI and true TB prevalence. Compared to PCF-only, untargeted ACF was estimated to improve life expectancy by 3.3 years (95% credible interval (CrI) [1.7, 5.4]) for individuals with TB disease, but at high cost. Targeted ACF covering half of the study population was estimated to identify 80% of all individuals with TB and achieved a lower cost per DALY averted (US$400, 95% CrI [20,1,000]) than untargeted ACF (US$700, 95% CrI [100, 1,500]). In the main analysis, these cost-effectiveness ratios exceeded available cost-effectiveness thresholds for Malawi, although cost-effectiveness improved under assumptions of higher TB prevalence or greater transmission reduction. The findings are based on mathematical modeling and are subject to several limitations, including assumptions regarding the relationship between ARTI and TB prevalence, which remains uncertain.
conclusionsTargeting ACF using Mtb immunoreactivity survey data could substantially improve health impact and cost-effectiveness compared to untargeted approaches. However, low-cost approaches for collecting these data are needed for wider adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.